Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease (IMMUNOPUMON2)

Université Catholique de Louvain

Status: Enrolling

Conditions: Sarcoidosis; Immune Dysregulation; Chronic Obstructive Pulmonary Disease; Lung Cancer (Diagnosis); Immunotherapy Resistance

Treatments: Other: Peripheral Blood Collection for Immune Profiling

Study type: Interventional

Funder types: Other

Identifiers

NCT07384897

IMMUNOPOUMON2

Details and patient eligibility

About

This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).

The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.

Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.

The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.

Enrollment: 425 estimated patients

Sex: All

Ages: Under 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Diagnosis of lung cancer
• Presence of precancerous lung lesions
• Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease [COPD]) prior to any treatment
• Control group: individuals without known lung disease
• Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD)
• Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected

Exclusion criteria

• Systemic corticosteroid therapy > 10 mg/day prednisone (or equivalent)
• Acute infection at the time of inclusion
• Refusal or inability to provide informed consent (or assent, when applicable)
• Chronic inflammatory lung disease currently treated with immunosuppressive therapy

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

425 participants in 6 patient groups

Patients with precancerous lung lesions

Other group

Description:

Patients with precancerous lung lesions under clinical monitoring

Treatment:

Other: Peripheral Blood Collection for Immune Profiling

Lung cancer

Active Comparator group

Description:

Patients with a diagnosis of lung cancer (all stages)

Treatment:

Other: Peripheral Blood Collection for Immune Profiling

Sarcoidosis and COPD

Other group

Description:

Patients with chronic inflammatory lung diseases

Treatment:

Other: Peripheral Blood Collection for Immune Profiling

Control group

Other group

Description:

Control group of volunteers without known lung disease

Treatment:

Other: Peripheral Blood Collection for Immune Profiling

chronic granulomatous disease

Other group

Description:

Children and adolescents weighing ≥10 kg with chronic granulomatous disease

Treatment:

Other: Peripheral Blood Collection for Immune Profiling

Adults undergoing orthopedic surgery following hip or femur fracture

Other group

Description:

Bone Marrow of Adults undergoing orthopedic surgery following hip or femur fracture

Treatment:

Other: Peripheral Blood Collection for Immune Profiling